Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) · National Institutes of Health
MEDIUM confidence
Researched 2026-07-22 22:43 · profile: researcher
Programme Thesis
The IGNITE R61/R33 program funds the development and validation of innovative model systems (e.g., cellular, tissue, or computational platforms) that accelerate neurotherapeutic discovery by improving predictive validity for CNS drug efficacy and safety. It exists to bridge the translational gap between basic neuroscience and clinical testing by supporting early-stage tool-building that can be broadly adopted by the research community.
Selection Criteria
1. Significance: Does the model system address a critical barrier in neurotherapeutic discovery (e.g., poor predictive validity, lack of human-relevant models)? 2. Innovation: Is the model system novel, technically rigorous, and likely to outperform existing approaches? 3. Approach: Are the development, validation, and dissemination plans well-defined, with clear milestones and quantitative success criteria? 4. Investigator(s): Does the team have complementary expertise in neurobiology, computational modeling, and translational pharmacology? 5. Environment: Does the applicant institution provide adequate resources and infrastructure? 6. Impact: Will the model system be scalable, reproducible, and accessible to other researchers (e.g., via open-source code, data sharing)?
Past Winners / Cohort Profiles
Past IGNITE awardees typically include U.S.-based academic labs (e.g., at Harvard, Stanford, UCSF) or small biotechs developing iPSC-derived neuronal models, organ-on-a-chip platforms, or advanced computational pipelines for target validation. Named examples are not listed on the page, but archetypes are: (a) a team building a humanized microphysiological system for blood-brain barrier transport, (b) a group creating a machine-learning-driven phenotypic screening assay for neuroinflammation, and (c) a consortium validating a novel rodent model for tauopathy.
Ideal Candidate Fingerprint
The platonic ideal applicant is a U.S.-based PI at an academic medical center or research institute with a track record in neurobiology and model system development, leading a multidisciplinary team that includes a computational expert and a translational pharmacologist. The proposal must demonstrate a clear path from model creation to validation against gold-standard neurotherapeutics, with strong letters of support from potential end-users.
Recommended Framing
Eniola should position the CCT model and its computational platforms (IMPRINT, TOPOLOGIX) as a novel, open-source model system for predicting addiction liability and neurotherapeutic efficacy, directly addressing IGNITE's goal of improving predictive validity. The strongest angle is to partner with a U.S.-based collaborator (e.g., Kent Berridge at Michigan or Samuel Gershman at Harvard) who can serve as the applicant organization, while Eniola contributes the core computational innovation and LMIC-relevant validation data. Emphasize the model's quantitative rigor (Bayesian validation, 85.8% encoding reduction) and its potential to reduce costly late-stage failures in addiction pharmacotherapy.
Watch Out
Hard eligibility barrier: The applicant must be a U.S. institution/organization; Eniola as an independent researcher in Nigeria cannot be the PI. No U.S. collaborator is yet confirmed. Additionally, the R61/R33 mechanism requires a two-phase plan with clear go/no-go milestones, which may be challenging to design without a U.S. lab's infrastructure. The program does not allow clinical trials, so any human-subjects component must be strictly model validation.